Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia

Daniel Casey, Søren Korsgaard, Jes Gerlach, Aage Jørgensen, Hans Simmelsgaard

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The endorphin neuropeptides may have neuroleptic-like effects on dopamine function and may be antischizophrenic. Ten chronic psychotic patients with neuroleptic-induced tardive dyskinesia and parkinsonism received placebo and des-tyrosine-γ-endorphin (DTγE). Drug effects on movement disorders and eye-blinking rates were assessed by blind evaluations of randomly sequenced videotapes made during standardized examinations before and 30, 60, and 120 minutes after each injection and at 24 hours postinjection on days of consecutive treatment. Changes in schizophrenic symptoms were evaluated openly with the schizophrenia subscale of the Comprehensive Psychiatric Rating Scale. There were no significant effects of DTγE on any parameter and no side effects. This suggests that DTγE, within the tested dose range, does not influence the pathophysiology of neuroleptic-induced dyskinesias or chronic schizophrenia or have neuroleptic properties. However, DTγE is well tolerated and should be tested with higher doses during prolonged treatment.

Original languageEnglish (US)
Pages (from-to)158-160
Number of pages3
JournalArchives of General Psychiatry
Volume38
Issue number2
DOIs
StatePublished - 1981

Fingerprint

Endorphins
Tyrosine
Antipsychotic Agents
Schizophrenia
Ocular Motility Disorders
Blinking
Videotape Recording
Dyskinesias
Parkinsonian Disorders
Neuropeptides
Psychiatry
Dopamine
Placebos
Tardive Dyskinesia
Dose
Injections
Therapeutics
Pharmaceutical Preparations
Movement Disorders
Rating Scales

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Casey, D., Korsgaard, S., Gerlach, J., Jørgensen, A., & Simmelsgaard, H. (1981). Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia. Archives of General Psychiatry, 38(2), 158-160. https://doi.org/10.1001/archpsyc.1981.01780270044005

Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia. / Casey, Daniel; Korsgaard, Søren; Gerlach, Jes; Jørgensen, Aage; Simmelsgaard, Hans.

In: Archives of General Psychiatry, Vol. 38, No. 2, 1981, p. 158-160.

Research output: Contribution to journalArticle

Casey, D, Korsgaard, S, Gerlach, J, Jørgensen, A & Simmelsgaard, H 1981, 'Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia', Archives of General Psychiatry, vol. 38, no. 2, pp. 158-160. https://doi.org/10.1001/archpsyc.1981.01780270044005
Casey, Daniel ; Korsgaard, Søren ; Gerlach, Jes ; Jørgensen, Aage ; Simmelsgaard, Hans. / Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia. In: Archives of General Psychiatry. 1981 ; Vol. 38, No. 2. pp. 158-160.
@article{b6e912d4ce234e7e8f8815eaa3185268,
title = "Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia",
abstract = "The endorphin neuropeptides may have neuroleptic-like effects on dopamine function and may be antischizophrenic. Ten chronic psychotic patients with neuroleptic-induced tardive dyskinesia and parkinsonism received placebo and des-tyrosine-γ-endorphin (DTγE). Drug effects on movement disorders and eye-blinking rates were assessed by blind evaluations of randomly sequenced videotapes made during standardized examinations before and 30, 60, and 120 minutes after each injection and at 24 hours postinjection on days of consecutive treatment. Changes in schizophrenic symptoms were evaluated openly with the schizophrenia subscale of the Comprehensive Psychiatric Rating Scale. There were no significant effects of DTγE on any parameter and no side effects. This suggests that DTγE, within the tested dose range, does not influence the pathophysiology of neuroleptic-induced dyskinesias or chronic schizophrenia or have neuroleptic properties. However, DTγE is well tolerated and should be tested with higher doses during prolonged treatment.",
author = "Daniel Casey and S{\o}ren Korsgaard and Jes Gerlach and Aage J{\o}rgensen and Hans Simmelsgaard",
year = "1981",
doi = "10.1001/archpsyc.1981.01780270044005",
language = "English (US)",
volume = "38",
pages = "158--160",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia

AU - Casey, Daniel

AU - Korsgaard, Søren

AU - Gerlach, Jes

AU - Jørgensen, Aage

AU - Simmelsgaard, Hans

PY - 1981

Y1 - 1981

N2 - The endorphin neuropeptides may have neuroleptic-like effects on dopamine function and may be antischizophrenic. Ten chronic psychotic patients with neuroleptic-induced tardive dyskinesia and parkinsonism received placebo and des-tyrosine-γ-endorphin (DTγE). Drug effects on movement disorders and eye-blinking rates were assessed by blind evaluations of randomly sequenced videotapes made during standardized examinations before and 30, 60, and 120 minutes after each injection and at 24 hours postinjection on days of consecutive treatment. Changes in schizophrenic symptoms were evaluated openly with the schizophrenia subscale of the Comprehensive Psychiatric Rating Scale. There were no significant effects of DTγE on any parameter and no side effects. This suggests that DTγE, within the tested dose range, does not influence the pathophysiology of neuroleptic-induced dyskinesias or chronic schizophrenia or have neuroleptic properties. However, DTγE is well tolerated and should be tested with higher doses during prolonged treatment.

AB - The endorphin neuropeptides may have neuroleptic-like effects on dopamine function and may be antischizophrenic. Ten chronic psychotic patients with neuroleptic-induced tardive dyskinesia and parkinsonism received placebo and des-tyrosine-γ-endorphin (DTγE). Drug effects on movement disorders and eye-blinking rates were assessed by blind evaluations of randomly sequenced videotapes made during standardized examinations before and 30, 60, and 120 minutes after each injection and at 24 hours postinjection on days of consecutive treatment. Changes in schizophrenic symptoms were evaluated openly with the schizophrenia subscale of the Comprehensive Psychiatric Rating Scale. There were no significant effects of DTγE on any parameter and no side effects. This suggests that DTγE, within the tested dose range, does not influence the pathophysiology of neuroleptic-induced dyskinesias or chronic schizophrenia or have neuroleptic properties. However, DTγE is well tolerated and should be tested with higher doses during prolonged treatment.

UR - http://www.scopus.com/inward/record.url?scp=0019523742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019523742&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1981.01780270044005

DO - 10.1001/archpsyc.1981.01780270044005

M3 - Article

VL - 38

SP - 158

EP - 160

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 2

ER -